Epivir (lamivudine)
- Region
- 🇪🇺 EU
- Active substance
- lamivudine
- Company
- ViiV Healthcare BV
- Status
- Authorised
- Therapeutic area
- HIV Infections
- EU approval
- Thu 08 Aug 1996
- Application
- EMEA/H/C/000107
- ATC
- J05AF05
- Official record
- www.ema.europa.eu
Indication
Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trizivir Withdrawn · ViiV Healthcare BV
- 🇪🇺 Lamivudine Teva Pharma B.V. Authorised · Teva B.V.
- 🇪🇺 Delstrigo Authorised · Merck Sharp & Dohme B.V.
- 🇪🇺 Zeffix Authorised · GlaxoSmithKline Trading Services Limited
- 🇪🇺 Dovato Authorised · ViiV Healthcare B.V.
- 🇪🇺 Triumeq Authorised · ViiV Healthcare B.V.
- 🇪🇺 Kivexa Authorised · ViiV Healthcare BV
- 🇪🇺 Lamivudine Teva Authorised · Teva B.V.
- 🇪🇺 Lamivudine/Zidovudine Teva Withdrawn · Teva Pharma B.V.
- 🇪🇺 Combivir Authorised · ViiV Healthcare BV
- 🇪🇺 Dutrebis Withdrawn · Merck Sharp Dohme Limited
Follow Epivir
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.